The Anticancer Properties of Tanshinones and the Pharmacological Effects of Their Active Ingredients

Li Fu¹, Bing Han², Yang Zhou¹, Jie Ren¹, Wenzhi Cao¹, Gopal Patel², Guoyin Kai¹,²* and Jun Zhang¹*

¹ School of Life Sciences, Institute of Plant Biotechnology, Shanghai Normal University, Shanghai, China; ² Laboratory of Medicinal Plant Biotechnology, College of Pharmaceutical Science, Zhejiang Chinese Medical University, Hangzhou, China

Cancer is a common malignant disease worldwide with an increasing mortality in recent years. *Salvia miltiorrhiza*, a well-known traditional Chinese medicine, has been used for the treatment of cardiovascular and cerebrovascular diseases for thousands of years. The liposoluble tanshinones in *S. miltiorrhiza* are important bioactive components and mainly include tanshinone IIA, dihydrodanshinone, tanshinone I, and cryptotanshinone. Previous studies showed that these four tanshinones exhibited distinct inhibitory effects on tumor cells through different molecular mechanisms *in vitro* and *in vivo*. The mechanisms mainly include the inhibition of tumor cell growth, metastasis, invasion, and angiogenesis, apoptosis induction, cell autophagy, and antitumor immunity, and so on. In this review, we describe the latest progress on the antitumor functions and mechanisms of these four tanshinones to provide a deeper understanding of the efficacy. In addition, the important role of tumor immunology is also reviewed.

Keywords: *Salvia miltiorrhiza*, tanshinones, autophagy, migration, tumor immunology, apoptosis

INTRODUCTION

Tanshinone is a natural terpenoid and the main bioactive component isolated from traditional Chinese medicine *Salvia miltiorrhiza*. It is traditionally used in the treatment of cardiovascular and cerebrovascular diseases in China (Chen et al., 2012; Shi et al., 2019; Sun et al., 2019). Modern pharmaceutical studies showed that tanshinone also possess antiangiogenic, antioxidant, antibacterial, anti-inflammatory, and antitumor activities (Wang et al., 2016; Gao et al., 2017; Zhou et al., 2017). According to the chemical structure, tanshinones could be classified into different types, out of which tanshinone IIA (Tan IIA), dihydrotanshinone (DT), tanshinone I (Tan I), and cryptotanshinone (CT) generally considered most important (Hao et al., 2016a; Shi et al., 2016a). Their chemical structures and physicochemical properties are summarized in Figure 1 and Table 1, respectively. The main precursor of tanshinones biosynthesis is geranyl diphosphate (GPP), which is derived from the mevalonate and the 2-C-methyl-d-erythritol-4-phosphate pathway (Kai et al., 2011; Shi et al., 2016b; Cao et al., 2018). A series of downstream enzymes were involved to catalyze the various steps of biosynthesis, and GPP finally transformed into tanshinones (Gao et al., 2009; Guo et al., 2013).
Tumor is a group of cells/tissues that has lost its control on the normal growth at the gene level due to the activation of various oncogenes or inactivation of tumor suppressors (Noda et al., 1999; Zhang et al., 2013). According to the size and growth characteristics, tumor tissue can be divided into malignant (cancerous) and benign (non-cancerous) (Avgerinou et al., 2017). Malignant tumor grows rapidly and often infiltrate to the surrounding tissues without envelops on the surface. The pathological examination indicated that these cells often exhibit atypical mitosis (Machado et al., 2016). Patients with advanced cancer often exhibited severe systemic symptoms and high recurrence rate after surgical excision, causing a big challenge for cancer therapy (Bax et al., 2016; Bendella et al., 2016; Frohman et al., 2016). In view of the enormous harm caused by cancer, the development of new antitumor treatments has become a research hotspot. Natural products are a good resource of antitumor compounds. In recent years, tanshinones have drawn scientists’ attention because of its broad-spectrum and effective antitumor activities. Their efficacy and the mechanisms have been excavated gradually. This article summarizes the latest researches on the antitumor effects and the mechanisms of the four tanshinones (Tan IIA, DT, Tan I, and CT). Current study may provide reference for the research and development of tanshinone compounds.

PHARMACOLOGICAL ACTIVITIES OF DIFFERENT TANSHINONE MONOMERS

Various studies showed that tanshinone compounds have a wide range of pharmacological effects, such as antibacterial, anti-inflammation, antioxidation, and antithrombosis (Zhou et al., 2017; Luo et al., 2019). With the excavating study, people also found the unique effect of tanshinones in the treatment of some diseases, such as diabetic cardiomyopathy (Tao et al., 2019), nephropathy (Liang et al., 2018), and diverse cancers. Here we
mainly summarized the antitumor effects of four tanshinone monomers; detailed description is as follows:

The Antitumor Function and Mechanism of Tan IIA

Tanshinone IIA appears as a kind of red crystalline substance that isolated from *S. miltiorrhiza*. Modern researches showed that Tan IIA has various physiological functions with extremely high medicinal value such as repair on myocardial damage, improvement of microcirculation, and extensive antitumor activity (Lin et al., 2006; Wang J. et al., 2013; Wang et al., 2014; Yang X. J. et al., 2018; Zhang Y. et al., 2018). Meanwhile, as one of the most severely studied monomers in *S. miltiorrhiza*, the antitumor activities and functions of Tan IIA have drawn more and more scientists’ attention. The various antitumor mechanisms of Tan IIA were shown in Figure 2 and discussed in details as follows.

Tan IIA Inhibits Tumor Cell Growth and Proliferation

Inhibition of tumor cell growth and proliferation is usually considered as the main strategy of anticancer compounds on diverse tumors. In general, endoplasmic reticulum (ER) stress, apoptosis induction, and cell cycle arrest can inhibit cell proliferation. Previous studies reported that Tan IIA may inhibit the growth and proliferation of various cancer cells, such as lung, breast, liver, leukemia, and colon cancer (Liu et al., 2006; Chen et al., 2012; Zhao et al., 2013; Lin C. Y. et al., 2017; Lu et al., 2018; Wang et al., 2018; Zhou et al., 2018). The ER stress response is usually defined as the unfolded protein response, which is an imbalance between the accumulations of unfolded or misfolded proteins in the ER lumen (Chen W. et al., 2019). Sustained ER stress activates protein interacting with C-kinase (PI3K), inositol-requiring enzyme 1 (IRE1), and activating transcription factor 6 (ATF6), leading to the activation of the proapoptotic factor C/EBP homologous protein (CHOP), which further promotes the activation of caspase-dependent apoptosis (Zhu et al., 2019). Previously, Tan IIA increased expression of protein kinase RNA-like ER kinase (PERK), ATF6, inositol-requiring enzyme 1α (IRE1α), caspase-12, and downstream eukaryotic initiation factor 2α (eIF2α), phosphorylated c-Jun N-terminal kinase (p-JNK), and CHOP to activate ER-mediated apoptosis in human pancreatic cancer BxPC-3 cells in vitro (Chiu and Su, 2017). Tan IIA also induced ER stress and apoptosis in human breast cancer BT-20 cells by increasing caspase-12, DNA damage-inducible gene 153 (GADD153), caspase-3, p-JNK, phospho-p38 mitogen-activated protein kinases (p-p38), and Bcl-2-Associated X protein (Bax) levels with decreased expression of B-cell lymphoma extra large (Bcl-xl) and p-ERK in a time- and dose-dependent manner (Yan et al., 2012). In another research, Tan IIA increased p53, p21, and Bax; decreased B-cell lymphoma-2 (Bcl-2), cell division cycle gene 2 (cdc2), and cdc25 expression; and induced ER-related apoptosis in hepatocellular carcinoma 15 cells through the regulation of calreticulin, caspase-12, and GADD153 expression (Cheng and Su, 2010). Additionally, Tan IIA inhibited the protective mitophagy through the inhibition of the adenosine monophosphate-activated kinase (AMPK), S-phase kinase–associated protein 2 (Skp2), Parkin pathway, leading to the mitochondria-mediated apoptosis of cancer cells (He and Gu, 2018).

The normal cell cycle circulation is driven by cyclin-dependent serine/threonine kinases and their regulated cyclin subunits. These proteins consist of cyclin-dependent kinases (CDKs), such as CDK2, CDK4, and CDK6, and cyclins, such as cyclin B, cyclin D, and cyclin E (Thanagaraj et al., 2019). The mutation and dysregulations of CDKs/cyclins lead to the uncontrolled cell proliferation (Marion et al., 2015). Tan IIA suppressed the growth of breast cancer MCF-7 cell line through arresting the S and G2 phase cell cycle by inhibiting the phosphoryldyninositol-3-kinase (PI3K), protein kinase B (Akt), mammalian target of rapamycin (mTOR), protein kinase C (PKC), rheumatoid arthritis (Ras), and mitogen-activated protein kinase (MAPK) signaling pathway. Interestingly, Tan IIA did not function as an Hsp90 inhibitor but could act synergistically with the Hsp90 inhibitors 17-AAG and ganetespib. Tan IIA inhibited the enzymatic activity of PKC especially the PKCζ and PKCε isoforms. Furthermore, the expression of antiapoptosis protein Bcl-2 was decreased, and the levels of cleaved caspase-3 and poly ADP-ribose polymerase (PARP) protein were increased after treatment with a certain concentration of Tan IIA for 24 h (Lv et al., 2018). Similarly, Tan IIA also plays a critical inhibitory role on diverse lung cancer cells. For instance, Tan IIA induced apoptosis and S phase cell cycle arrest in lung cancer PC9 cells by regulating the PI3K-Akt signaling pathway (Liao et al., 2019). Besides, combination of Tan IIA and adriamycin significantly up-regulated the expression of cleaved caspase-3 and Bax and down-regulated the expression of vascular endothelial growth factor (VEGF), VEGFR2, p-PI3K, p-Akt, Bcl-2, and caspase-3; induced apoptosis; and arrested cell cycle at the S and G2 phases in A549 cells (Xie et al., 2016).

The antitumor efficacy of Tan IIA was also found in other malignancies. Signal transducer and activator of transcription 3 (STAT3) is a member of signal-responsive transcription factors and plays a pivotal role in tumorigenesis (Chen et al., 2017; Wang et al., 2017). Activation of the STAT3 signal directly stimulates the expression of forkhead box M1 (FOXM1), which is a regulator of cell cycle (André et al., 2012; Tan et al., 2014). This evidence revealed that STAT3 constitutively activated in gastric cancer. Zhang and his colleagues showed that Tan IIA could suppress gastric cancer cells growth by down-regulating STAT3 and FOXM1 expression (Zhang Y. et al., 2018). Furthermore, Tan IIA could inhibit osteosarcoma MG-63 cell proliferation and achieve its best inhibitory effect with 8.8 mg/L of Tan IIA (Zhang et al., 2012b; Ma et al., 2016a,b). Tan IIA treatment also induced cell apoptosis and arrested cell cycle in human oral cancer KB cells line by mitochondrial pathway via activation of caspase-3, caspase-9, and PARP (Tseng et al., 2014), by MDM4-1AP3 signaling pathway in lung cancer H1299 cells (Zu et al., 2018), and by inducing the formation of cleaved caspase-8 and cleavage of RIP1, RIP3, and MLKL in human hepatocellular carcinoma HepG2 cells (Lin C. Y. et al., 2016).

Tan IIA Inhibits Tumor Cell Invasion and Migration

It is well known that the recrudescence after operation and metastasis are the major causes of death in cancer patients. The
FIGURE 2 The antitumor mechanism of Tan IIA. Tanshinone IIA inhibits cancer cell proliferation, induces differentiation and apoptosis through MAPK, AMPK/Skp2/Parkin, ER stress and mitochondrial pathway, inhibits of invasion and migration through Notch1/NF-κB signaling, induces of autophagy in cancer cells through PI3K/Akt/mTOR signaling pathway, and inhibits angiogenesis by inhibiting the activity of VEGF. The arrow represents the promotion effect, and the T area represents the inhibition effect.

invasion and migration are two key factors that contributed to the recurrence and metastasis of cancer cells (Lin et al., 2007; Nurnberg et al., 2011). Therefore, effective suppression of tumor invasion and metastasis might be an important part for cancer therapy (Yang et al., 2015). Previous in vivo and in vitro studies showed that Tan IIA could inhibit the invasion and migration of colon cancer cells (Su and Lin, 2008; Su et al., 2012). High dose of Tan IIA was shown to inhibit astrocytoma migration through up-regulating transmembrane receptor notch homolog 1 (Notch-1) pathway and down-regulating matrix metalloproteinase-9 (MMP-9), cellular-myelocytomatosis viral oncogene (c-Myc), and Bcl-2 expression (Dong W. et al., 2018). FOXM1 is a member of the FOX family and associated with cell fate decisions. Overexpression of FOXM1 promoted tumor progression and metastasis (Tan et al., 2014). Tan IIA could down-regulate FOXM1, MMP-2, and MMP-9 expression in gastric cancer SGC7901 cell line, resulting in the suppression of proliferation and migration in a dose-dependent way (Yu et al., 2017).

Tan IIA Inhibits Tumor Angiogenesis

Angiogenesis is a vital step in the physiological process of tissue repair and regeneration, bone remodeling and reproduction, and embryonic development (Folkman, 2006; Garona et al., 2018; Annese et al., 2019). Moreover, it also played a critical role in the progression of tumor formation, infiltration, invasion, and metastasis (Carmeliet, 2006; Seano et al., 2014; Lii et al., 2016; Ao et al., 2017; Yang et al., 2017). Thus, inhibition of angiogenesis has become an effective strategy for cancer therapy. VEGF is a key factor in the production and release of angiogenesis in tumor tissues under hypoxia. There are eight members of the gene family: VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, VEGF-F, and placenta growth factor-1 (PIGF-1) and PIGF-2. It has many functions, including stimulating angiogenesis, recruiting new blood vessels, inflammation, and vascular permeability through angiogenic, which constitutes the most important signal pathway in tumor angiogenesis (Xie et al., 2017). In a recent study, Tan IIA dramatically suppressed; VEGF promoted the migration and tube formation of human endothelia progenitor cells through the phospholipase C (PLC), Akt, and JNK signaling pathways without cytotoxic effect (Lee et al., 2017). Meanwhile, Tan IIA was found to effectively restrain β-catenin/VEGF-mediated angiogenesis by targeting transforming growth factor-β (TGF-β1) in normoxic and hypoxia-inducible factor 1α (HIF-1α) in hypoxic microenvironments in human colorectal cancer (Sui et al., 2017). Tan IIA exhibited antiangiogenic effects in vivo and in vitro by modulating the secretion of MMP-2 and TIMP-2 (Tsai et al., 2011). Other studies also suggested that Tan IIA could
inhibit angiogenesis in some cells, such as osteosarcoma cells, breast cancer cells, and vascular endothelial cells (Li et al., 2015; Xing et al., 2015; Huang et al., 2017).

**Tan IIA Induces Tumor Cell Autophagy**

Cell autophagy is an important physiological process in organism development. Basal autophagy is essential to the normal metabolism of cells, which process waste by removing damaged organelles and protein aggregates (Qiu et al., 2017). The latest research focused on autophagy has made great progress in the understanding of the antitumor mechanisms of Tan IIA. Autophagy involves multiple signaling pathways, such as the AMPK and PI3K/Akt/mTOR signaling pathways (Yang et al., 2019; Zhou et al., 2019). AMPK consists of a catalytic subunit ($\alpha$) and two regulatory subunits $\beta$ ($\beta_1$ and $\beta_2$) and $\gamma$ ($\gamma_1$, $\gamma_2$, and $\gamma_3$). AMPK regulated variety of biochemical pathways, which control the signal of cellular energy metabolism, whereas its dysfunction is associated with many human diseases (Ge et al., 2019). mTOR is present in both mTORC1 and mTORC2 complexes and has a negative regulatory effect on autophagy. PI3K/Akt and AMPK pathways have positive and negative regulation of mTORC1 effect, respectively (Yang et al., 2019).

In another study, Tan IIA induced autophagic cell death via activation of AMPK and ERK and inhibition of mTOR and rapamycin (mTOR), ribosomal protein S6 kinase (p70 S6K) in KMB-5 leukemia cells (Yun et al., 2013; Han et al., 2018). Moreover, it was pointed that the survival of osteosarcoma cell could be inhibited by Tan IIA through the PI3K/AKT signaling pathway, indicating that Tan IIA could effectively induce autophagy in human osteosarcoma cells (Yen et al., 2018). Analogously, Tan IIA induced autophagocytosis of tumor cells by activating autophagic-related Beclin-1 and light chain 3-II (LC3-II) expression in melanoma A375 cells (Li et al., 2017). In addition, Tan IIA might induce the autophagy in oral squamous cell carcinoma by both activating the Beclin-1/Atg7/Atg12-Atg5 pathway and inactivating the PI3K/Akt/mTOR pathway (Ye et al., 2018). Another recent study proved that Tan IIA suppressed colorectal cancer cell growth, decreased mitochondrial membrane potential, and inhibited mitophagy through inactivation of AMPK/Skp1/Parkin pathway (He and Gu, 2018).

**Tan IIA Induces Tumor Immune Checkpoint Blockade**

Programmed cell death-ligand 1 (PD-L1) expressed on various cancer cells played a protective role against the cytotoxicity of immune cells. It interacts with programmed cell death-1 receptor (PD-1) to inhibit the cytotoxicity of T cells and block the antitumor immune response. Thus, dismissing immune suppression using immune checkpoint blockade agents is helpful for cancer therapy. Tan IIA was shown to inhibit breast cancer BT-20 cells by inhibiting the expression of PD-L1, cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), and cluster of differentiation 80 (CD80) (Su, 2018). In addition, Tan IIA enhanced interleukin 15 (IL-15)–mediated natural killer (NK) cell differentiation via activation of p38MAPK pathway (Kim et al., 2012).

**The Antitumor Activities of Tan IIA in vivo**

To study the antitumor activity and function of a potential anticancer drug, in vivo experiments are often necessary and more convincing. In recent years, more and more in vivo studies revealed the unique antitumor activity of Tan IIA. Here, the main antitumor studies of Tan IIA in vivo are summarized in Table 2. Using Lewis lung cancer mice model, intraperitoneal injection of Tan IIA at 15 mg/kg significantly inhibited tumor growth, neovascularization, and Bcl-2 expression and increased the levels of CD4+, CD4+/CD8+, and NK cells. Moreover, combination of Tan IIA with cyclophosphamide (CTX) showed potent efficacy (Li et al., 2016). Endothelial progenitor cells (EPCs) usually derive from bone marrow that are generally considered as the key regulator in tumor angiogenesis and metastasis (Ashallara et al., 1999; Adams et al., 2012; Mund et al., 2012). Tan IIA was first proved to reduce EPC angiogenesis by inhibiting PLC, Akt, and JNK signaling pathways in a chick embryo chorioallantoic membrane model and Matrigel plug assay in mice, indicating that Tan IIA might be the new potential treatment of angiogenesis-related cancers (Lee et al., 2017). In an acute promyelocytic leukemia (APL) NOD/SCID mice model, Tan IIA was found to prolong the survival of APL-bearing mice, prevent APL-mediated body weight reduction, and inhibit the proliferation of APL cells by inducing apoptosis and differentiation (Zhang et al., 2016). Moreover, in NOD-SCID mice xenografted with human osteosarcoma 143B cells, Tan IIA inhibited the expression of CD31 and mitochondrial fusion proteins Mfn1/2 and Opal, increased the expression of dynamic-related protein 1 (Drp1), induced apoptosis and antiangiogenesis (Huang et al., 2017). In gastric cancer AGS cell xenograft SCID mice model, results showed that treatment with Tan IIA for 8 weeks significantly reduced the protein expression levels of epidermal growth factor receptor (EGFR), inverted gravity flame reactor (IGFR), PI3K, AKT, and mTOR and inhibited AGS cell proliferation by blocking the PI3K/AKT/mTOR pathway (Su and Chiu, 2016). In BxPC-3-derived xenograft tumor model, treatment with Tan IIA induced ER stress by up-regulating the levels of PERK, ATF6, caspase-12, IRE1α, eIF2α, p-JNK, CHOP, and caspase-3 and inhibited the tumor growth in vivo (Chiu and Su, 2017).

According to these studies, it can be concluded that Tan IIA is a promising natural product and deserves further study for cancer therapy. The further detailed research on the antitumor mechanism of Tan IIA will have a clearer understanding about the antitumor function, targets, and the whole regulation network of Tan IIA. Based on this, it may provide a new and effective antitumor strategy for the treatment of cancer.

**The Antitumor Function and Mechanism of CT**

CT is an important active component in *S. miltiorrhiza* and considered as one of the most effective antineoplastic constituents in tanshinone compounds. Many studies showed that CT significantly inhibited the growth of a variety of tumor cells in addition to its antibacterial and anti-inflammatory activities (Shi et al., 2014; Yu et al., 2014; Hao et al., 2015; Zhou et al., 2016).
The antitumor mechanisms of CT are shown in Figure 3. STAT3 is one of the most frequently activated members of the STAT family and plays an important role in the proliferation, survival, invasion, and angiogenesis signaling pathways of various tumors. Abnormal activation of JAK/STAT3 signaling is associated with tumor progression, tumor microenvironment, and immune evasion (Chen et al., 2017; Ke et al., 2017a; Wang et al., 2017). Interleukin 6 is a representative stimulant of STAT3 signaling pathway. CT was identified as a potent STAT3 inhibitor that inhibited the phosphorylation of STAT3 Tyr705 and the target proteins such as survivin, Bcl-XL, and cyclin D1 through blocking the dimerization in DU145 prostate cancer cells (Shin et al., 2019). CT induced apoptosis of esophageal EC109 cancer cells by inhibiting p-STAT3 (Tyr705) and p-JAK2 without effect on the expression of the total STAT3 and JAK2 in vitro and in vivo (Ji et al., 2019). It is confirming that the antisaphegal cancer effect of CT was associated with the inhibition of IL-6–mediated activation of JAK2/STAT3 signaling pathway (Ji et al., 2019). Similarly, CT was found to have strong inhibition effects on malignant gliomas (MGs) but also preliminarily explored its potential mechanisms through a series of experiments in vivo and in vitro. In this study, they elaborated that CT could inhibit the proliferation of MG by suppressing the phosphorylation of STAT3 Tyr705 through activating the tyrosine phosphate activity of SHP-2 protein (Lu et al., 2017). Furthermore, CT could significantly suppress the growth and colony-forming of HCCC-9810 and RBE cells by inducing apoptosis in a dose-dependent manner. The underlying mechanism contributed to the inhibition of the JAK2/STAT3 and PI3K/Akt/nuclear factor-κB (NF-κB) pathways. Their work may provide a possible effective treatment for cholangiocarcinoma (Ke et al., 2017b). Aerobic glycolysis is a hallmark of cancer and also called Warburg effect. CT inhibited the expression of glycolysis-related proteins including glucose transporter 1 (GLUT1), hexokinase 2 (HK2), and lactate dehydrogenase A (LDHA) in ovarian cancer Hey cells and xenograft nude mice by repressing STAT3/SIRT3/HIF-1α signaling pathway (Yang Y. et al., 2018). CT inhibited p-STAT5 and p-STAT3, effectively blocked IL-6–mediated STAT3 activation, and reversed chronic myeloid leukemia (CML) fusion gene (BCR-ABL) kinase-independent drug resistance and inhibited key cell coproliferation and drug resistance pathway of K562/ADR in CML (Dong B. et al., 2018). Another study showed that CT induced cell cycle arrest and apoptosis of multidrug-resistant leukemia cell line K562/ADM by inhibiting the expression of cyclin D1, Bcl-2, and elf4E (Ge et al., 2012). Simultaneously, CT induced autophagic cell death in multidrug-resistant colon cancer cell line SW620 Ad300 via ROS-p38 MAPK–NF-κB signaling pathway (Xu et al., 2017).

Inducing apoptosis of tumor cells is generally considered to be a major mean for the efficacy of antitumor drugs, and it is no exception for CT. For example, CT inhibited the proliferation of human cancer cell A549 and H1299. Detailed studies demonstrated that CT exerted its inhibition effect by down-regulating the insulin-like growth factor 1 receptor (IGF-1R), PI3K/Akt signaling pathway. The insulin-like growth factor 1 (bIGF-1) induced IGF-1R and AKT phosphorylation, suggesting that it may become a potential clinical therapeutic agent for the treatment of human lung cancer (Zhang J.)
CT induced S-phase cell cycle arrest, apoptosis, and mitochondrial fragmentation in osteosarcoma cells with increased Bax, Bad, and Bak; decreased Bcl-2; and the activation of caspase-3, caspase-8, and caspase-9 expressions. Further data confirmed that CT directly promoted the interaction of Drp1 with Bax, directly, which promoted the translocation of Bax from cytoplasm to mitochondria, resulting in the apoptotic fragmentation of mitochondria (Yen et al., 2019). In a recent study, CT induced apoptosis in melanoma cell lines and increased the sensitivity of A375 cell line to tumor necrosis factor (TNF)–related apoptosis-inducing ligand (TRAIL), which further led to the enhancement of cell death in melanoma cells (Radhika et al., 2018). DNA topoisomerase 2 is an important nuclear enzyme, which regulates cell proliferation by modulating DNA topology and chromatid separation. Treatment with CT dramatically decreased the stabilization of topoisomerase 2a at mRNA level and showed anticancer effect against human prostate cancer in vitro and in vivo (Kim et al., 2017). In addition, CT also inhibited mTORC1 expression through activating AMPK–TSC2 axis in Rh30 cells (Chen W. et al., 2019). CT induced autophagy by activating JNK signaling through increasing intracellular reactive oxygen species (ROS) formation (Hao et al., 2016b).

As we mentioned earlier, angiogenesis plays a key role in providing oxygen and nutrition for tumor growth and metastasis. Therefore, it has been considered as a potential target for cancer therapy (Yu et al., 2002; Guo et al., 2012; Boreddy and Srivastava, 2013). Studies showed that CT also plays a unique role in this respect. CT inhibited tumor angiogenesis in lipopolysaccharide (LPS)–induced neovascular sprouts in zebrafish embryos and vascularization in mouse Matrigel plug model. Moreover, CT could suppress VEGF–induced tube formation and sprout of human umbilical vein endothelial cells (HUVECs) in vitro. Tumor necrosis factor α is generally considered as a key angiogenic factor that is related to both NF-κB and STAT3 pathways. Their further study pointed out that CT could cause the reduction of RNA-binding factor HuR stability and inhibited angiogenesis through posttranscriptional mechanism of TNF-α mediated by NF-κB and STAT3 pathways (Zhu et al., 2016). Basic fibroblast growth factor (bFGF) is a proangiogenic factor that stimulates the migration and spreading of endothelial cell invasion. CT suppressed bFGF-stimulated angiogenesis of bovine aortic endothelial cells in vitro. However, Tan II A showed no effect at the same concentration. CT and Tan II A have similar structures except C-15 position of dihydrofuran ring. This might infer that the double bond at C-15 position of dihydrofuran ring contributed to the antiangiogenesis efficacy (Hur et al., 2005). In another research, CT inhibited tubular-like structure formation and decreased
VEGF expression and LiCl-induced β-catenin augmentation in HUVECs. Thus, CT-mediated angiogenesis was associated with the inhibition of Wnt/β-catenin signaling pathway (Chen et al., 2014).

Cryptotanshinone may also exert its anticancer function by enhancing the activity of other antitumor drugs. As we know, arsenic trioxide (ATO) is often used in the treatment of advanced liver cancer. Combined treatment of ATO with CT showed potent inhibition effect on the growth of Bel-7404 cells than ATO or CT alone. Meanwhile, the combination caused the obvious changes in the expression level of antiapoptotic proteins (depressing XIAP, Bcl-2, and survivin) and apoptotic proteins (promoting Bak), which lead to the suppression of tumor growth (Shen et al., 2017). In addition, CT could enhance the sensitivity of ovarian cancer A2780 cells and showed favorable effect on various solid tumors and could sensitize A2780 cells to cisplatin treatment in a dose-dependent manner (Jiang et al., 2017).

Immunosuppressive tumor microenvironment can lead to tumor-evading immunotherapy, so immunosuppression is a major problem in antitumor therapy. Tumor tissues are infiltrated by immunosuppressive cells such as regulatory T cells and myeloid-derived suppressor cells, and M2-polarized TAMs, which produce inhibitors such as PD-1/PD-L1, lymphocyte and myeloid-derived suppressor cells, and M2-polarized TAMs, infiltrated by immunosuppressive cells such as regulatory T cells with elevated expression of CD80, CD86, TNF-α, IL-1β, and IL-12p70 through the activation of NF-κB, p38, and JNK expression. CT -induced DC maturation is dependent on MyD88 expression because the effects were compromised in MyD88−/− DC. Encouragingly, mice bearing established Lewis lung tumors were cured by CT alone or more effective when combined with anti–PD-L1. Data further demonstrated that CT plus low doses of anti–PD-L1 generated LLC-specific antitumor immune response and immunological memory as resultant tumor-free mice were resistant to rechallenge with LLC, but not B16 melanoma (Liu et al., 2019). Natural killer cells are a subset of lymphocytes crucial for innate and adaptive immune responses that are triggered in the presence of IL-15. CT was shown to increase IL-15–induced NK cell differentiation through enhancing the phosphorylation of p38 MAPK and the expression of transcription factors, such as T-box transcription factor TBX21 (T-bet), GATA-binding protein 3 (GATA-3), inhibitor of DNA binding 2 (Id2), and ETS proto-oncogene 1(ETS-1) (Kim et al., 2012). The antitumor immune mechanisms of CT in different cells are shown in Figure 4.

To sum up, as another lipid-soluble active component of S. miltiorrhiza, CT plays an important role in inducing tumor cell apoptosis; inhibiting tumor cell proliferation, invasion, and angiogenesis; and enhancing the activity of other antitumor drugs. However, the study on the antitumor function and mechanism of CT is still in its initial stage, and there are some deficiencies in the analysis of the whole antitumor regulatory network. It is still necessary to perform further studies on CT in terms of molecular biology, cell biology, receptor pharmacology, and so on.

The Antitumor Function and Mechanism of Tan I
Tan I also inhibited both the mRNA and protein expression of MMP-2 and MMP-9, which are crucial for tumor metastasis. The underlying mechanism can be concluded as the down-regulation of the JAK/STAT3 signaling pathway (Wang et al., 2012). The antitumor immune mechanisms of CT in different cells are shown in Figure 4.
Similarly, Tan I attenuated proliferation, colony formation, and cisplatin resistance of cervical cancer. The expression of p-AKT and kainate receptors (KARS) was markedly suppressed by Tan I treatment. In contrast, overexpression of KRAS or ETS-like I transcription factor (ELK1) markedly impaired the suppression of Tan I on HeLa cells (Dun and Gao, 2018).

In the research of Li et al., Tan I showed the most potent effect on the proliferation of lung cancer cells compared with CT and Tan IIA. Tan I also induced apoptosis and G2/M cell cycle arrest in vitro; inhibited the expression of Aurora A, survivin, cyclin B, cdc2, and CDK2; and increased the ratio of Bax/Bcl-2. Aurora A–specific siRNA confirmed that Aurora A is a potential target for Tan I. In addition, H1299 xenograft mice oral gavaged with Tan I at a dose of 200 mg/kg exhibited the marked reduction of tumor weight, angiogenesis, and Aurora A expression in vivo (Li et al., 2013). Tan I was explored that could cause the death of tumor multidrug resistance cells by inducing PARP, caspase-3, -8, and -9 cleavages and decreasing mitochondria membrane potential without influence on drug transporter proteins P-glycoprotein (P-gp) and multidrug resistance protein 1 (MRP1). It enhanced the depression of p-705-STAT3 and the secondary activation of p38, AKT, and ERK-involved signaling networks (Xu et al., 2013). Moreover, Tan I was also proven to induce the apoptosis of prostate cancer cells and enhance its sensibility to TRAIL (Shin et al., 2018).

The Antitumor Function and Mechanism of DT

Dihydrotanshinone is also an important component of tanshinone compounds. However, there is still less research on its antitumor functions and mechanisms compared to the other three monomers. DT exhibited special biological inhibitory activities on diverse tumors (Chen X. et al., 2019). The antitumor mechanisms of DT are shown in Figure 6. DT inhibited the growth of liver cancer cells with an EC\textsubscript{50} (50% effective concentration) value of 2.52 \(\mu\)M. In this study, DT induced caspase-3, -8, and -9 cleavages in a concentration-dependent manner. Moreover, DT significantly induced phosphorylation of P54 and P46 SAPK/JNK (Thr183/TYR185) and p38MAPK (th180/bar182), increased Bax and decreased cytochrome c in mitochondria after p38 MAPK activation, but significantly inhibited PARP cleavage after p38 MAPK inhibition. This indirectly demonstrates that ROS-mediated phosphorylation of p38MAPK is involved in a certain extent in the apoptosis of human hepatoma HepG 2 cells induced by DT (Lee et al., 2009). Cancer stem cells (CSCs) play a key role in tumor metastasis and recurrence. DT activated NOX5 to generate ROS and then phosphorylate STAT3 expression, reduce IL-6 secretion, and induce CSC death (Kim et al., 2019). Similarly, DT exhibited strong cytotoxicity in HCT116 p53(-/-) and HCT116 p53(+/+) colon cancer cells and induced PARP...
cleavage in a time-dependent manner. They further observed that DT decreased mitochondria membrane potential and stimulated mitochondria to produce ROS, causing a decrease in mitochondrial metabolites and ROS leakage. However, DT-induced apoptosis was inhibited by the ROS scavenger NAC or catalase–PEG alone, confirming that DT impairs mitochondrial function. These results also suggested that DT induced apoptosis of colon cancer cells through a p53-independent but ROS-dependent pathway (Wang L. et al., 2013). In multidrug-resistant colon cancer cell line SW620 Ad300, DT, and CT were shown to induce accumulation of LC3B-II and increase autophagy flux. In addition, the cytotoxic effects of the two tanshinones were independent of p53, suggesting that both DT and CT inhibited the growth of multidrug-resistant colon cancer cells by inducing autophagic cell death in a p53-independent manner (Hu et al., 2015). Recently, DT-I decreased the expression of MMP-9, MMP-2, MMP-7, Snail, and N-cadherin, thus inhibiting the migration and invasion of osteosarcoma cells. Besides, DT-I increased the expression of PARP and caspase-3, decreased the expression of Bcl-2, and induced apoptosis of osteosarcoma cells through mitochondrial pathway. DT I down-regulated the expression of β-catenin, IRP6 (upstream of β-catenin), c-Myc (downstream of β-catenin), and cyclin D1 protein and suppressed Wnt/β-catenin signaling. In an in vivo mouse model, DT-I showed inhibited formation of osteosarcoma. These results suggested that DT-I inhibited the proliferation, migration, and invasion and induced apoptosis of osteosarcoma cells in vivo and in vitro by inhibiting Wnt/β-catenin signaling pathway (Tan et al., 2019). DT activated the activity of caspase-3, caspase-9, PARP, and cytochrome c release; inhibited proliferation of glioma cell; and induced apoptosis in SHG-44 cells (Cao et al., 2017). Moreover, DT had an antiproliferative effect on human hepatocellular carcinoma cells. DT could induce cell cycle arrest of SK-HEP-1 cells at G0/G1 phase, which led to the inhibition of tumor cell growth by down-regulating the expression of cyclin D1, cyclin A, cyclin E, CDK4, CDK2, c-Myc, and retinoblastoma protein (p-Rb) expression with increased expression of the CDK inhibitor p21, suggesting that the antiproliferative activity of DT is related to the regulation of AMPK/AKT/mTOR and MAPK signaling pathways (Hong et al., 2018). In addition, DT could obviously inhibit the angiogenesis of infantile hemangioma by up-regulating several apoptosis-related proteins, such as caspase-3, caspase-8, PARP, AIF, Bax, cytochrome c, and so on (Cai et al., 2018). Lin et al. accessed data from the Taiwan Computerized Insurance Reimbursement Claims Database and used National Health Insurance Research Database (NHIRD) analysis to find out that S. miltiorrhiza has a protective effect on colon cancer patients in clinical practice. DT inhibited protein expression of Skp2, Smad nuclear interacting protein 1 (Snip1), and Ras homolog gene family member A (RhoA) and induced
apoptosis of HCT116 cells and HT-29 cells by reducing the secretion of CCL2 in macrophages and blocking the recruitment of colon cancer cells. DT treatment also reduced tumor burden in xenograft nude mice (Lin Y. Y. et al., 2017).

The Antitumor Activities of Other Tanshinone Compounds

There are also many other liposoluble compounds in *S. miltiorrhiza* except those elaborated above, including Tan IIB, isocryptotanshinone, hydroxytanshinone, and so on (Li et al., 2018). These compounds also exhibit antitumor activities on various cancers. For example, isocryptotanshinone was proven as a STAT3 inhibitor that could induce the apoptosis and autophagy of A549 lung cancer cells (Guo et al., 2016). Isocryptotanshinone treatment down-regulated the expression of cell cycle and apoptosis-related proteins cyclin D1, phosphorylated Rb, E2F transcription factor 1 (E2F1), myeloid cell leukemia 1 (Mcl-1), Bcl-2, and survivin expression; inhibited the phosphorylation of STAT3; and induced cell cycle arrest at G1/G0 phase, thereby inhibiting the proliferation of gastric cancer cells. In addition, isocryptotanshinone also inhibited the gastric tumor growth of BALB/c nude mice *in vivo* (Chen et al., 2018). Moreover, isocryptotanshinone down-regulated the expression of Bcl-2 and Bcl-xl proteins; up-regulated the expression of Bax, Bak, PARP, caspase-3, and caspase-9; induced cell cycle arrest at G1 phase; and decreased mitochondrial membrane permeability in MCF-7 cells. Phosphorylation of JNK, ERK, and p38 MAPK was induced by time and concentration dependence, and the MAPK signal was activated to inhibit the proliferation of MCF-7 cells (Zhang et al., 2015). S222 and S439 are derivatives of Tan I that exhibited anti–multidrug resistance and antiangiogenic properties. In a panel of 15 cancer cell lines, S222 and S439 inhibited STAT3 phosphorylation, induced DNA double-strand breaks, blocked cell cycle at G2/M phase, and induced apoptosis (Tian et al., 2018). Acetyl tanshinone IIA (ATA) is a compound obtained by chemical modification of Tan IIA. Acetyl tanshinone IIA induced G1/S phase arrest and apoptosis in HER2-positive MDA-MB-453, SK-BR-3, and BT-47 breast cancer cells by inhibiting receptor tyrosine kinases (RTKs) EGFR/HER2 and downstream survival signaling pathways. Moreover, ATA significantly inhibited tumor growth in athymic MDA-MB-453 xenograft mouse (Guerram et al., 2015). Acetyl tanshinone IIA inhibited the growth of breast cancer cells and the growth of xenografted mouse by inducing the production of ROS and up-regulating the expression of Bax, cytochrome c, and caspase-3 in breast cancer cells (Tian et al., 2010). PTS33, a sodium derivative of CT, could selectively inhibit prostate cancer cells growth by inhibiting the expression of androgen receptor (AR) protein and blocking the expression of AR-regulated genes (Xu et al., 2012). Neo-tanshinlactone, a natural product isolated from *S. miltiorrhiza*, could selectively inhibit the proliferation of

FIGURE 6 | The antitumor mechanism of DT. Dihydrotanshinone inhibits cancer cell proliferation and induces apoptosis by mediating signals such as Wnt/β-Catenin, AMPK/Akt/mTOR, MAPK, CCL2, and p21 and inhibits the invasion and migration of cancer cells and angiogenesis by inhibiting MMP-2, MMP-9, and VEGFR2 signals. The arrow represents the promotion effect, and the T area represents the inhibition effect.
estrogen receptor–positive breast cancer cells by inhibiting the synthesis of ESR1 mRNA and down-regulating the transcription of estrogen receptor α (Lin W. et al., 2016). DYZ-2-90 is a novel ring-opening compound modified by neo-tanshinlactone that induced ERK-mediated cell division arrest and apoptosis in human colorectal cancer cells by activating the stress-related JNK pathway (Wang et al., 2012), although there are still few studies on the anticancer effect of these liposoluble monomers. We believe that with the deepening of research, their unique antitumor functional activities will be gradually excavated.

THE CLINICAL CHALLENGES OF TANSHINONES

In recent years, there have been more and more studies on the anticancer effects of tanshinones. However, because tanshinones have a high hydrophobicity, it is difficult to prepare an injection, and the absorption is poor at the time of oral administration or injection. Poor bioavailability has been a major challenge for pharmaceutical development. Studies have shown that the structural modification of tanshinone compounds can solve the solubility problem to some extent and improve the limitation of tanshinones in clinical application (Zhang et al., 2012a).

CONCLUSION AND PERSPECTIVES

Traditional Chinese herbal medicine are important sources of antitumor drugs. From their initial use (in the treatment of cardiovascular and cerebrovascular diseases) to the unique antitumor activities, researches on tanshinone compounds have made a great progress. In the last decade, numerous studies have demonstrated the antitumor properties of tanshinones on various tumors both in vitro and in vivo. Tanshinones exerted a broad range of antitumor functions such as the induction of apoptosis and autophagy; regulation of cell cycle; inhibition of proliferation, invasion, metastasis, and angiogenesis; and enhancement of immunology. It suggests that tanshinones especially Tan IIA and CT may become a potential antitumor agent and provide a new therapeutic strategy for human cancers.

REFERENCES

Adams, E. L., Yoder, E. M., and Kasdan, M. L. (2012). Giant cell tumor of the tendon sheath: experience with 65 cases. Eplasty 12:e50.

André, L. M., Renata, B., Gerson, M. F., Barbara, D. R., and Eliana, A. (2012). Forkhead Box M1 (FoxM1) gene is a new STAT3 transcriptional factor target and is essential for proliferation, survival and DNA repair of K562 cell line. PLoS One 7:e48160. doi: 10.1371/journal.pone.0048160

Annese, T., Tamma, R., Ruggieri, S., and Ribatti, D. (2019). Erythropoietin in tumor angiogenesis. Exp. Cell Res. 374, 266–273. doi: 10.1016/j.yexcr.2018.12.013

Ao, Z., Yu, S., Qian, P., Gao, W., Gao, R., Dong, X., et al. (2017). Tumor angiogenesis of SCLC inhibited by decreased expression of FMOD via downregulating angiogenic factors of endothelial cells. Biomed. Pharmacother. 87, 539–547. doi: 10.1016/j.biopha.2016.12.110

Asahara, T., Yano, M., Fukuda, S., Fukuda, T., Nakahara, H., Katayama, K., et al. (1999). Brain metastasis from hepatocellular carcinoma after radical hepatectomy. Hiroshima J. Med. Sci. 48, 91–94.

The investigations on the signaling pathways help us to have a better understanding on the antitumor mechanisms of tanshinones. However, process and pathways are usually extremely large and complicated; because of this, our understanding is quite limited. Besides, studies have proven CT having a potent antitumor immune function, whereas there are few reports on other tanshinone compounds. Because of their similar chemical structures, it can be speculated that they may also possess the immunosuppressive effect. However, further investigation is needed. Meanwhile, the in vivo antitumor experiments of the four tanshinones are quite few especially for Tan I and DT. Besides, there is still no strong evidence whether it has cytotoxicity on normal cells. This might be a limit for further clinical application. Therefore, more preclinical or clinical trials are also a direction of future research.

AUTHOR CONTRIBUTIONS

LF consulted literatures and drafted the manuscript. BH, YZ, JR, WC, and GP participated in manuscript sorting. JZ and GK revised the manuscript.

FUNDING

This work was supported by the National Natural Science Fund of China (81522049, 81670151, 31571735, and 31270007), the “Dawn” Program of Shanghai Education Commission (16SG38), Open project of Shanghai Key Laboratory Atmospheric Particle Pollution Prevention (C-6105-17-029), Shanghai Science and Technology Committee Project (17JC1404300 and 15430502700), Zhejiang Provincial Ten Thousands Program for Leading Talents of Science and Technology Innovation, Zhejiang Provincial Program for the Cultivation of High-level Innovative Health talents, Opening project of Zhejiang provincial preponderant and characteristic subject of Key University (Traditional Chinese Pharmacology), and Zhejiang Chinese Medical University (ZYAOXYB2019005 and ZYAOX2018019).

Avgerinou, C., Giannezi, I., Theodoropoulou, S., Lazaris, V., Koliopoulou, G., Zikos, P., et al. (2017). Occupational, dietary, and other risk factors for myelodysplastic syndromes in western greece. Hematology 22, 419–429. doi: 10.1080/10245332.2016.1277006

Bax, M. J., Johnson, T. M., Harms, P. W., Schwartz, J. L., Zhao, L., Fullen, D. R., et al. (2016). Detection of occult invasion in Melanoma in situ. JAMA Dermatol. 152, 1201–1208. doi: 10.1001/jamadermatol.2016.2668

Bendella, H., Brackmann, D. E., Goldbrunner, R., and Angelov, D. N. (2016). Nerve crush but not displacement-induced stretch of the intra-arachnoidal facial nerve promotes facial palsy after cerebellopontine angle surgery. Exp. Brain Res. 234, 2905–2913. doi: 10.1007/s00221-016-4692-7

Boreddy, S. R., and Srivastava, S. K. (2013). Deguelin suppresses pancreatic tumor growth and metastasis by inhibiting epithelial-to-mesenchymal transition in an orthotopic model. Oncogene 32, 3980–3991. doi: 10.1038/onc.2012.241

Cai, Y., Lv, F., Kaldybayeva, N., Zhamilya, A., Wu, Z., and Wu, Y. (2018). 15, 16-Dihydrotanshinone I inhibits hemangiomas through inducing pro-apoptotic
and Anti-angiogenic mechanisms in vitro and in vivo. Front. Pharmacol. 9:25. doi: 10.3389/fphar.2018.00025
Cao, W., Wang, Y., Shi, M., Hao, X., Zhao, W., Wang, Y., et al. (2018). Transcription factor SmWRKY1 positively promotes the biosynthesis of tanshinones in salvia miltiorrhiza. Front. Plant Sci. 9:554. doi: 10.3389/fpls.2018.00554
Cao, Y., Huang, B., and Gao, C. (2017). Salvia miltiorrhiza extract dihydrotanshinone induces apoptosis and inhibits proliferation of glioma cells. Jpn J. Basic Med. Sci. 17, 235–240. doi: 10.17350/jbms.2017.1800
Carmeliet, E. (2006). Action potential duration, rate of stimulation, and intracellular sodium. J. Cardiovasc. Electrophysiol. 17(Suppl. 1), S2–S7. doi: 10.1111/j.1540-8167.2006.00378
Chen, J., Bi, Y., Chen, L., Zhang, Q., and Xu, L. (2018). Tanshinone IIA regulates colorectal cancer apoptosis. Biomed. Pharmacother. 104, 530–536. doi: 10.1016/j.biopha.2018.05.040
Chen, J., Shi, D. Y., Liu, S. L., and Zhong, L. (2012). Tanshinone IIA induces growth inhibition and apoptosis in gastric cancer in vitro and in vivo. Oncol. Rep. 27, 523–528. doi: 10.3892/or.2011.1524
Chen, Q., Zhuang, Q., Mao, W., Xu, X. M., Wang, L. H., and Wang, H. B. (2014). Inhibitory effect of cryptotanshinone on angiogenesis and Wnt/β-catenin signaling pathway in human umbilical vein endothelial cells. Chin J. Integr. Med. 20, 743–750. doi: 10.1007/s11655-014-1810-x
Chen, W., Pan, Y., Wang, S., Liu, Y., Chen, G., Zhou, L., et al. (2019). Correction to: Cryptotanshinone activates AMPK-TSC2 axis leading to inhibition of mTORC1 signaling in cancer cells. BMC Cancer 19:257. doi: 10.1186/s12885-019-5458-y
Chen, X., Yu, J., Zhong, B., Lu, J., Lu, J. J., Li, S., et al. (2019). Pharmacological activities of dihydrotanshinone I, a natural product from salvia miltiorrhiza bunge. Pharmazie. Res. 145:104254. doi: 10.1016/j.phrs.2019.104254
Chen, Z., Zhu, R., Zheng, J., Chen, C., Huang, C., Ma, J., et al. (2017). Cryptotanshinone inhibits proliferation yet induces apoptosis by suppressing STAT3 signals in renal cell carcinoma. Oncotarget 8, 50023–50033. doi: 10.18632/oncotarget.18483
Cheng, C. Y., and Su, C. C. (2010). Tanshinone IIA inhibits Hep-7 cells by increasing calreticulin, caspase 12 and GADD153 protein expression. Int. J. Mol. Med. 26, 379–385.
Chiu, T. L., and Su, C. C. (2017). Tanshinone IIA increases protein expression levels of PERK, ATF6, IRE1α, CHOP, caspase-3 and caspase-12 in pancreatic cancer BxPC-3 cell-derived xenograft tumors. Mol. Med. Rep. 15, 3259–3263. doi: 10.3892/mmr.2017.6359
Dong, B., Liang, Z., Chen, Z., Li, B., Zheng, L., Yang, J., et al. (2018). Cryptotanshinone suppresses key onco-proliferative and drug-resistant pathways of chronic myeloid leukemia by targeting STAT5 and STAT3 phosphorylation. Sci. China Life Sci. 61, 999–1009. doi: 10.1007/s11427-018-9324-y
Dong, W., Zhang, Y., Chen, X., and Jia, Y. (2018). High-Dose tanshinone IIA suppresses migration and proliferation while promoting apoptosis of astrocytoma cells via notch-1 pathway. Neurochem. Res. 43, 1855–1861. doi: 10.1007/s11064-018-2601-0
Dun, S., and Gao, L. (2018). Tanshinone I attenuates proliferation and chemoresistance of cervical cancer in a KRAS-dependent manner. J. Biochem. Mol. Toxicol. 33:e22267. doi: 10.1002/jbt.22267
Folkman, J. (2006). Antiangiogenesis in cancer therapy—endostatin and its mechanisms of action. Exp. Cell Res. 312, 594–607. doi: 10.1016/j.yexcr.2005.11.015
Frohman, L., Wong, A. B., Matheos, K., Leon-Alvarado, L. G., and Danesh-Meyer, H. V. (2016). New developments in giant cell arteritis. Surv. Ophthalmol. 61, 400–421. doi: 10.1016/j.survophth.2016.01.001
Gao, H., Liu, X., Sun, W., Kang, N., Liu, Y., Yang, S., et al. (2017). Total tanshinones exhibits anti-inflammatory effects through blocking TLR4 dimerization via the MyD88 pathway. Cell Death Dis. 8:e3004. doi: 10.1038/cdddis.2017.389
Gao, W., Hillwig, M. L., Huang, L., Cui, G., Wang, X., Kong, J., et al. (2009). A functional genomics approach to tanshinone biosynthesis provides stereochemical insights. Org. Lett. 11, 5170–5173. doi: 10.1021/ol902051
Liao, X. Z., Gao, Y., Huang, S., Chen, Z. Z., Sun, L. L., Liu, J. H., et al. (2019). Anti-tumor and chemosensitization effects of Cryptotanshinone extracted from Salvia miltiorrhiza Rge. on ovarian cancer cells in vitro. *J. Ethnopharmacol.* 205, 33–40. doi: 10.1016/j.jep.2017.04.026

Kai, G., Xu, H., Zhou, C., Liao, P., Xiao, J., Luo, X., et al. (2011). Metabolic engineering tanshinone biosynthetic pathway in salvia miltiorrhiza hairy root cultures. *Metab. Eng.* 13, 319–327. doi: 10.1016/j.ymben.2011.02.003

Ke, F., Wang, Z., Song, X., Ma, Q., Hu, Y., Jiang, L., et al. (2017a). Cryptotanshinone induces cell cycle arrest and apoptosis through the JAK2/STAT3 and PI3K/Akt/ NFκB pathways in cholangiocarcinoma cells. *Drug Des. Devel. Ther.* 11, 1753–1766. doi: 10.2147/DDDT.S132488

Ke, F., Zheng, W., Xiaoding, S., Qiang, M., Yunping, H., Lin, J., et al. (2017b). Cryptotanshinone induces cell cycle arrest and apoptosis through the JAK2/STAT3 and PI3K/Akt/NFκB pathways in cholangiocarcinoma cells. *Drug Des. Devel. Ther.* 11, 1753–1766.

Kim, E. J., Kim, S. Y., Kim, S. M., and Lee, M. (2017). A novel topoisoerase 2a inhibitor, cryptotanshinone, suppresses the growth of PC3 cells without apparent cytotoxicity. *Toxicol. Appl. Pharmacol.* 1, 84–92. doi: 10.1016/j.taap.2017.07.007

Kim, S. L., Choi, H. S., Kim, J. H., Jeong, D. K., Kim, K. S., and Lee, D. S. (2019). Dihydrotanshinone-Induced NOX5 activation inhibits breast cancer stem cell through the ROS/STAT3 signaling pathway. *Oxid. Med. Cell. Longev.* 2019:926943. doi: 10.1155/2019/926943

Kim, W. S., Kim, D. O., Yoon, S. J., Kim, M. J., Yoon, S. R., Park, Y. J., et al. (2012). Cryptotanshinone and tanshinone IIA enhance IL-15-induced natural killer cell differentiation. *Biochem. Biophys. Res. Commun.* 425, 340–347. doi: 10.1016/j.bbrc.2012.07.093

Lee, C. Y., Sher, H. F., Chen, H. W., Liu, C. C., Chen, C. H., Lin, C. S., et al. (2009). Anicancer effects of tanshinone I in human non-small cell lung cancer. *Mol. Cancer Ther.* 7, 3527–3538. doi: 10.1158/1535-7163.MCT-07-2288

Lee, H. P., Liu, Y. C., Chen, P. C., Tai, H. C., Li, T. M., Fong, Y. C., et al. (2017). Tanshinone IIA inhibits angiogenesis in human endothelial progenitor cells in vitro and in vivo. *Oncotarget* 8, 109217–109227. doi: 10.18632/oncotarget.22649

Lee, W. Y., Liu, K. W., and Yeung, J. H. (2009). Reactive oxygen species-mediated kinase activation by dihydrotanshinone in tanshinones-induced apoptosis in HepG2 cells. *Cancer Lett.* 285, 46–57. doi: 10.1016/j.canlet.2009.04.040

Li, G., Shan, C., Liu, L., Zhou, T., Zhou, J., Hu, X., et al. (2015). Tanshinone IIA inhibits HIF-1α and VEGF expression in breast cancer cells via mTOR/p70S6K/RPS6/4E-BP1 signaling pathway. *PLoS One* 10:e0117440. doi: 10.1371/journal.pone.0117440

Li, Q., Hu, K., Tang, S., Xu, L. F., and Luo, Y. C. (2016). Anti-tumor activity of tanshinone IIA in human umbilical ven endothelial cell injured by hydrogen peroxide and its mechanism. *J. Ethnopharmacol.* 24, 217–222. doi: 10.1016/j.jep.2006.05.004

Lin, T. S., Huang, H. H., Fan, Y. H., Chioiu, S. H., and Chow, K. C. (2007). Genetic polymorphism and gene expression of microsomal epoxide hydrase in non-small cell lung cancer. *Oncol. Rep.* 17, 565–572.

Lin, W., Huang, J., Liao, X., Yuan, Z., Feng, S., Xie, Y., et al. (2016). Neotanshin lactone selectively inhibits the proliferation of estrogen receptor positive breast cancer cells through transcriptional down-regulation of estrogen receptor alpha. *Pharmacol. Res.* 111, 849–858. doi: 10.1016/j.phrs.2015.09.003

Lin, Y. Y., Lee, I. Y., Huang, W. S., Lin, Y. S., Kuan, F. C., Shu, L. H., et al. (2017). Danshen improves survival of patients with colon cancer and dihydroxytanshinone I inhibits the proliferation of colon cancer cells via apoptosis and skp2 signaling pathway. *Eur. J. Pharmacol.* 209, 305–316. doi: 10.1016/j.ejphar.2017.08.011

Liu, J. J., Lin, D. J., Liu, P. Q., Huang, M., Li, X. D., and Huang, R. W. (2006). Induction of apoptosis and inhibition of cell adhesive and invasive effects by tanshinone IIA in acute promyelocytic leukemia cells in vitro. *J. Biomed. Sci.* 13, 813–823. doi: 10.1007/s11373-006-9110-x

Liu, S., Zhen, H., Anna, I. T., Hongsheng, L., Sean, H., De, Y., et al. (2019). Cryptotanshinone has curative dual anti-proliferative and immunotherapeutic effects on mouse Lewis lung carcinoma. *Cancer Immun. Immunother.* 68, 1059–1071. doi: 10.1007/s00262-019-02326-8

Lu, L., Zhang, S., Li, C., Zhou, C., Li, D., Liu, P., et al. (2017). Cryptotanshinone inhibits human glioma cell proliferation in vitro and in vivo through SHP-2-dependent inhibition of STAT3 activation. *Cell Death Dis.* 8:e2767. doi: 10.1038/cddiscovery.2016.65

Lu, M., Luo, Y., Hu, P., Dou, L., and Huang, S. (2018). Tanshinone IIA inhibits AEGs-induced proliferation and migration of cultured vascular smooth muscle cells by suppressing ERK1/2 MAPK signaling. *Iran J. Basic Med. Sci.* 21, 83–88. doi: 10.22038/IJBMS.2017.20100.5276

Luo, J., Zhang, L., Zhang, X., Long, Y., Zou, F., Yan, C., et al. (2019). Protective effects and active ingredients of Salvia miltiorrhiza Bunge extracts on airway responsiveness, inflammation and remodeling in mice with ovalbumin-induced allergic asthma. *Phytomedicine* 52, 168–177. doi: 10.1016/j.phymed.2018.09.170

Lv, C., Zeng, H. W., Wang, J. X., Yuan, X., Zhang, C., Fang, T., et al. (2018). The antitumor natural product tanshinone IIA inhibits protein kinase C and acts synergistically with 17-AAG. *Cell Death Dis.* 9:165. doi: 10.1038/s41419-017-0247-5

Ma, K., Zhang, C., Huang, M. Y., Guo, X. Y., and Hu, G. Q. (2016a). Crosstalk between Bcl-2 dependent apoptosis and caspase-dependent apoptosis induced by tanshinone IIA in human osteosarcoma MG-63 cells. *Oncol. Rep.* 36, 1807–1818. doi: 10.3892/or.2016.5003

Ma, K., Zhang, C., Huang, M. Y., Li, Y. W., and Hu, G. Q. (2016b). Cinnobufagine induces apoptosis-mediated cell death in human osteosarcoma U2OS cells through the ROS/INKP38 signaling pathway. *Oncol. Rep.* 36, 90–98. doi: 10.3892/or.2016.4782

Machado, I., Cruz, J., Lavernia, J., and Llombart-Bosch, A. (2016). Solitary, multiple, benign, atypical, or malignant: the “Granular Cell Tumor” puzzle. *Virchows Arch.* 468, 527–538. doi: 10.1007/s00428-015-1877-6

Marion, P., Camille, P., Morgan, P., and May, C. M. (2015). Targeting Cyclin-Dependent Kinases in Human Cancers: From Small Molecules to 3-kinase/Akt signalling pathway. *Phytother. Res.* 33, 2298–2309. doi: 10.1002/ptr.6392
Peptide Inhibitors. *Cancers (Basel)* 7, 179–237. doi: 10.3390/cancers701 0179

Mund, J., Ingram, D. A., and Yoder, M. C. (2012). “Defining endothelial progenitor cells,” in *Regenerative Therapy Using Blood-Derived Stem Cells. Stem Cell Biology and Regenerative Medicine*, eds D. Allan and D. Strunk (Totowa, NJ: Humana Press). doi: 10.1007/978-1-61779-471-1_2

Dihydrotanshinone I inhibits gastric carcinoma AGS cells both in vitro and in vivo. *Onco. Rep.* 36, 1173–1179. doi: 10.3829/or.2016.4857

Su, C. C., and Lin, Y. H. (2008). Tanshinone IIA down-regulates the protein expression of ErbB-2 and up-regulates TNF-alpha in colon cancer cells in vitro and in vivo. *Int. J. Mol. Med.* 22, 847–851.

Sui, H., Zhao, J., Zhou, L., Ren, W., Deng, W., Li, C., et al. (2017). Tanshinone IIA inhibits beta-catenin/VEGFR-mediated angiogenesis by targeting TGF-beta1 in normoxic and HIF-1alpha in hypoxic microenvironments in human colorectal cancer. *Cancer Lett.* 403, 86–97. doi: 10.1016/j.canlet.2017.05.013

Sun, M., Shi, M., Wang, Y., Huang, Q., Yuan, T., Wang, Q., et al. (2019). The biosynthesis of phenolic acids is positively regulated by the JA-responsive transcription factor ERF115 in Salvia miltiorrhiza. *J. Exp. Bot.* 70, 243–254. doi: 10.1093/jxb/ery349

Tan, G., Liang, C., Yuanhui, C., Li, Y., and Yongtian, T. (2014). Foxm1 mediates LIF/Stat3-dependent self-renewal in mouse embryonic stem cells and is essential for the generation of induced pluripotent stem cells. *PLoS One* 9:e92304. doi: 10.1371/journal.pone.0092304

Tao, S., Chen, L., Song, J., Zhu, N., Song, X., Shi, R., et al. (2019). Dihydrotanshinone I inhibits the growth of osteosarcoma through the Wnt/beta-catenin signaling pathway. *Onc. Targets Ther.* 12, 5111–5122. doi: 10.2147/OTT.S204574

Tian, H. L., Yu, T., Xu, N. N., Feng, C., Zhou, L. Y., Luo, H. W., et al. (2010). A novel compound modified from tanshinone inhibits tumor growth in vivo via activation of the apoptotic pathway. *Cancer Lett.* 297, 18–30. doi: 10.1016/j.canlet.2010.04.020

Tian, Q. T., Ding, C. Y., Song, S. S., Wang, Y. Q., Zhang, A., and Miao, Z. H. (2018). New tanshinone I derivatives 2222 and S439 similarly inhibit topoisomerase II/II but reveal different p53-dependency in inducing G2/M arrest and apoptosis. *Biochem. Pharmacol.* 154, 255–264. doi: 10.1016/j.bcp.

Tseng, P. Y., Lu, W. C., Hsieh, M. J., Chien, S. Y., and Chen, M. K. (2014). Tanshinone IInduces apoptosis in human oral cancer KB cells through a mitochondria-dependent pathway. *Biomed. Res. Int.* 2014, 540516. doi: 10.1155/2014/540516

Wang, H., Su, X., Fang, J., Xin, X., Zhao, X., Gaur, U., et al. (2018). Tanshinone IIA Attenuates Insulin Like Growth Factor 1 -Induced Cell Proliferation in PC12 Cells through the PI3K/Akt and MEK/ERK Pathways. *Int J Mol. Int 2014, 540516. doi: 10.1155/2014/540516

Wang, H., Su, X., Fang, J., Xin, X., Zhao, X., Gaur, U., et al. (2018). Tanshinone IIA Attenuates Insulin Like Growth Factor 1 -Induced Cell Proliferation in PC12 Cells through the PI3K/Akt and MEK/ERK Pathways. *Int J Mol. Int 2014, 540516. doi: 10.1155/2014/540516

Wang, H., Su, X., Fang, J., Xin, X., Zhao, X., Gaur, U., et al. (2018). Tanshinone IIA Attenuates Insulin Like Growth Factor 1 -Induced Cell Proliferation in PC12 Cells through the PI3K/Akt and MEK/ERK Pathways. *Int J Mol. Int 2014, 540516. doi: 10.1155/2014/540516

Wang, L., Yeung, J. H., Hu, T., Lee, W. Y., Lu, L., Zhang, L., et al. (2013). Dihydrotanshinone induces p53-independent but ROS-dependent apoptosis in colon cancer cells. *Life Sci.* 93, 344–351. doi: 10.1016/j.lfs.2013.07.007

Wang, L. T., Pan, S. L., Chen, T. H., Dong, Y., Lee, K. H., and Teng, C. M. (2012). DYZ-2-90, a novel neo-tanshinlactone ring-opened compound, induces ERK-mediated mitotic arrest and subsequent apoptosis by activating JNK in human colorectal cancer cells. *ChemBiochem.* 13, 1663–1672. doi: 10.1002/chem.201201756

Wang, W., Li, J., Ding, Z., Li, Y., Wang, J., Chen, S., et al. (2019). Tanshinone I inhibits the growth and metastasis of osteosarcoma via suppressing IAK/STAT3 signalling pathway. *J. Cell Mol. Med.* 23, 6454–6456. doi: 10.1111/jcmm.14539
Yen, J. H., Huang, S. T., Huang, H. S., Fong, Y. C., Wu, Y. Y., Chiang, J. H., et al. (2017). Tanshinone IIA combined with adriamycin inhibited malignant biological behaviors of NSCLC A549 cell line in a synergistic way. BMC Cancer 16:899. doi: 10.1186/s12885-016-2921-x

Xie, L., Tao, J., and Wei, G. (2017). Anti-angiogenesis target therapy for advanced osteosarcoma. Oncol. Rep. 38, 625–636. doi: 10.3892/or.2017.5735

Yong, H. M., Le, Y., Dong, X. Z., and Yong, Y. B. (2016). Cryptotanshinone inhibits lung tumor growth by increasing CD4+ T cell cytotoxicity through activation of the JAK2/STAT4 pathway. Oncol. Lett. 12, 4094–4098. doi: 10.3892/ol.2016.5123

Yu, J., Wang, X., Li, Y., and Tang, B. (2017). Tanshinone IIA suppresses gastric cancer cell proliferation and migration by downregulation of FOXM1. Oncol. Rep. 37, 1394–1400. doi: 10.3892/or.2017.5408

Yu, J., Zhai, D., Hao, L., Zhang, D., Bai, L., Cai, Z., et al. (2014). Cryptotanshinone reverses reproductive and metabolic disturbances in PCOS model rats via regulating the Expression of CYP17 and AR. Evid Based Compl. Alternat Med. 2014:760743. doi: 10.1155/2014/760743

Yu, J. L., Comber, B. L., and Kerbel, R. S. (2002). A paradox for therapy-induced microenvironmental changes in solid tumors leading to drug resistance. Differentiation 70, 599–609. doi: 10.1016/S0161-6919(02)00039-1

Yu, M., Xiaobui, D., Yujun, C., Fang, Z., Shuqi, J., Shisong, H., et al. (2019). Multifunctional nanoregulator resheses immune microenvironment and enhances immune memory for tumor immunotherapy. Adv. Sci. 6:1900037. doi: 10.1002/advs.201900037

Yun, S.-M., Jung, J. H., Jeong, S.-J., Sohn, E. J., Kim, B., and Kim, S.-H. (2013). Tanshinone IIA induces autophagic cell death via activation of AMPK and ERK and inhibition of mTOR and p70 S6K in KRM-5 leukemia cells. Phytother Res. 28, 458–464. doi: 10.1002/ptr.30145

Zhou, Y., Qianqian, Z., Yangyang, K., Xiaohong, G., Haiyan, Z., Huqin, F., et al. (2019). Insulin Like Growth Factor Binding Protein Related Protein 1 Activates Primary Hepatic Stellate Cells via Autophagy Regulated by the PI3K/Akt/mTOR Signaling Pathway. Dig. Dis. Sci. 65, 509–523. doi: 10.1007/s10620-019-05798-x

Zhang, G., Hoersch, S., Amsterdam, A., Whittaker, C. A., Beert, E., Catchen, J. M., et al. (2013). Comparative oncogenic analysis of copy number alterations in human and zebrafish tumors enables cancer driver discovery. PLoS Genet. 9:e1003734. doi: 10.1371/journal.pgen.1003734

Zhang, J., Wen, G., Sun, L., Yuan, W., Wang, R., Zeng, Q., et al. (2018). Cryptotanshinone inhibits cellular proliferation of human lung cancer cells C downregulation ofIGF-1R/PI3K/Akt signaling pathway. Oncol. Rep. 40, 2926–2934. doi: 10.3892/or.2018.6638

Zhang, K., Li, J., Meng, W., Xing, H., and Yang, Y. (2016). Tanshinone IIA inhibits acute promyelocytic leukemia cell proliferation and induces their apoptosis in vivo. Blood Cells Mol. Dis. 56, 46–52.

Zhang, X., Luo, W., Zhao, W., Lu, J., and Chen, X. (2015). Isocryptotanshinone induced apoptosis and activated MAPK signaling in human breast cancer MCF-7 cells. J. Breast Cancer 18, 112–118. doi: 10.4048/jbc.2015.18.2.112

Zhang, Y., Guo, S., Fang, J., Peng, B., Zhang, Y., and Cao, T. (2018). Tanshinone IIA inhibits cell proliferation and tumor growth by downregulating STAT3 in human gastric cancer. Exp. Ther. Med. 13, 2931–2937. doi: 10.3892/etm.2018.6270

Zhang, Y., Jie, J., Meng, W., Cai, Q.-C., and Jiang, Y. (2015). Potential roles of EZH2, Bmi-1 and miR-203 in cell proliferation and invasion in hepatocellular carcinoma cell line Hep3B. World J. Gastroenterol. 21, 13268–13276. doi: 10.3748/wjg.v21.i47.13268

Ye, Q., Conghua, L., Qianhua, W., Xingqi, Z., and Ping, J. (2018). Tanshinone IIA induces cell death via Beclin-1-dependent autophagy in oral squamous cell carcinoma SCC-9 cell line. Cancer Med. 7, 397–407. doi: 10.1002/cam4.1691

Zhou, W., Huang, Q., Wu, X., Zhou, Z., Ding, M., Shi, M., et al. (2017). Comprehensive transcriptome profiling of Salvia miltiorrhiza for discovery of genes associated with the biosynthesis of tanshinones and phenolic acids. Sci. Rep. 7:10554. doi: 10.1038/s41598-017-10215-2

Zhou, Y., Zhang, T. B., Bao, C. H., Chen, X. Y., Wang, Y., and Wang, Q. (2013). Physical properties of gastrointestinal stromal tumors based on atomic force microscope analysis. Genet. Mol. Res. 12, 5774–5785. doi: 10.4238/2013.70108.672

Zhou, M., Zhou, G., Hu, S., and Zhang, L. (2018). Tanshinone IIA suppress the proliferation of mRNA-1 nasopharyngeal carcinoma an in vitro study. J. Cancer Sci. 5:527–528. doi: 10.4172/2155-9585.1000144

Zhou, Y., Wu, X., Zhou, Z., Ding, M., Shi, M., et al. (2017). Comprehensive transcriptome profiling of Salvia miltiorrhiza for discovery of genes associated with the biosynthesis of tanshinones and phenolic acids. Sci. Rep. 7:10554. doi: 10.1038/s41598-017-10215-2

Zhou, Y., Sun, W., Chen, J., Tan, H., Xiao, Y., Li, Q., et al. (2016). SmMyc2a and SmMyc2b played similar but irreplaceable roles in regulating the biosynthesis of tanshinones and phenolic acids in Salvia miltiorrhiza. Sci. Rep. 6:22852. doi: 10.1038/srep22852

Zhu, M., Jiang, Y., Wu, H., Shi, W., Lu, G., Cong, D., et al. (2019). Gambogic Acid Shows Anti-Proliferative Effects on Non-Small Cell Lung Cancer (NSCLC)
Cells by Activating Reactive Oxygen Species (ROS)-Induced Endoplasmic Reticulum (ER) Stress-Mediated Apoptosis. Med. Sci. Monit. 25, 3983–3988. doi: 10.12659/MSM.916835

Zhu, Z., Zhao, Y., Li, J., Tao, L., Shi, P., Wei, Z., et al. (2016). Cryptotanshinone, a novel tumor angiogenesis inhibitor, destabilizes tumor necrosis factor-alpha mRNA via decreasing nuclear-cytoplasmic translocation of RNA-binding protein HuR. Mol. Carcinog. 55, 1399–1410. doi: 10.1002/mc.22383

Zu, Y., Wang, J., Ping, W., and Sun, W. (2018). Tan IIA inhibits H1299 cell viability through the MDM4IAP3 signaling pathway. Mol. Med. Rep. 17, 2384–2392. doi: 10.3892/mmr.2017.8152

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Fu, Han, Zhou, Ren, Cao, Patel, Kai and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
**APPENDIX**

**Abbreviations:** Akt, protein kinase B; AMPK, adenosine monophosphate-activated kinase; ATA, acetyltanshinone IIA; ATF6, activating transcription factor 6; B7-1 (CD80), cluster of differentiation 80; Bad, Bcl-2-associated death promoter; Bak, Bcl-2 Antagonist Killer; Bax, Bcl-2-Associated X protein; Bcl-2, B-cell lymphoma-2; Bcl-xl, B-cell lymphoma extra large; BCR-ABL, chronic myeloid leukemia (CML) fusion gene; bFGF, basic fibroblast growth factor; cdc2, cell division cycle gene 2; CDKs, cyclin-dependent kinases; CHOP, C/EBP homologous protein; c-Myc, cellular-myelocytomatosis viral oncogene; CT, cryptotanshinone; CTLA-4, cytotoxic T-lymphocyte-associated antigen 4; Drp1, dynamic-related protein 1; DT, dihydrotanshinone; E2F1, E2F transcription factor 1; EGFR, epidermal growth factor receptor; elf2a, eukaryotic initiation factor 2α; ELK1, ETS-like 1 transcription factor; ETS-1, ETS proto-oncogene 1; FOXM1, forkhead box M1; GADD153, DNA damage-inducible gene 153; GATA-3, GATA binding protein 3; GLUT1, glucose transporter 1; HGI-estrin 2, HPK1/GCK-like sestrin 2; HIF-1α, hypoxia-inducible factor 1α; HK2, hexokinase 2; Id2, inhibitor of DNA biding 2; IFNα, Interferon α; IGF-1R, insulin-like growth factor 1 receptor; IGFR, inverted gravity flame reactor; IL-15, interleukin 15; iNOS, inducible nitric oxide synthase; IRE1, inositol-requiring enzyme 1; JAK2, Janus Kinase II; KARS, kainate receptors; LC3-II, light chain 3-II; LDHA, lactate dehydrogenase A; MAPK, mitogen-activated protein kinase; Mcl-1, myeloid cell leukemia 1; MDM4–IAP3, murine double minute 4- inhibitor of apoptosis 3; Mfn1/2, mitochondrial mitofusins proteins; MLKL, mixed-lineage kinase domain-like pseudokinase; MMP-9, matrix metalloproteinase-9; MRP1, multidrug resistance protein 1; mTOR, mammalian target of rapamycin; MyD88, myeloid differentiation protein 88; NF-kB, nuclear factor-b; Notch-1, transmembrane receptor notch homolog 1; Opal, optic Atrophy 1; p70 S6K, rapamycin (mTOR), ribosomal protein S6 kinase; PARP, poly ADP-ribose polymerase; PD-1, programmed cell death-1 receptor; PD-L1, programmed cell death-ligand 1; PERK, protein kinase RNA-like ER kinase; P-gp, P-glycoprotein; PI3K, phosphatidylinositol-3-kinase; PICK, protein interacting with C-kinase; PIGF, placenta growth factor; p-JNK, phosphorylated c-Jun N-terminal kinase; PKC, protein kinase C; PLC, phospholipase C; p-p38, phosphoprotein-associated mitogen-activated protein kinases; p-Rb, retinoblastoma protein; Ras, rheumatoid arthritis; RhoA, Ras homolog gene family member A; RIP1, receptor interacting protein kinase 1; ROS, reactive oxygen species; RTKs, receptor tyrosine kinases; SAPK, stress-activated protein kinases; SESN2, sestrin 2; Skp2, S-phase kinase–associated protein 2; Snip1, Smad nuclear interacting protein 1; STATs, Signal transducers and activators of transcription; Tan I, tanshinone I; Tan IIA, tanshinone IIA; T-bet, T-box transcription factor TBX21; TGF-β1, transforming growth factor-beta; TLR7, toll-like receptor 7; TRAIL, TNF-related apoptosis-inducing ligand; VEGF, vascular endothelial growth factor; XIAP, X-linked inhibitor of apoptosis.